Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2013 17:00 ET | Source: Receptos, Inc.

Receptos to Hold Third Quarter 2013 Financial Results Conference Call and Webcast

SAN DIEGO, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
October 02, 2013 02:00 ET | Source: Receptos, Inc.

Receptos to Deliver Scientific Presentations About RPC1063 at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

SAN DIEGO, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Receptos Inc. (Nasdaq:RCPT) today announced that Company personnel will deliver two scientific poster presentations about RPC1063 at the annual meeting of...
September 18, 2013 08:00 ET | Source: Receptos, Inc.

Receptos to Present at BioCentury Newsmakers Conference

SAN DIEGO, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
August 13, 2013 08:00 ET | Source: Receptos, Inc.

Receptos Announces Issuance of Composition of Matter Patents Covering Proprietary Lead Product Candidate RPC1063

SAN DIEGO, Aug. 13, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
August 08, 2013 08:00 ET | Source: Receptos, Inc.

Receptos to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 8, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
August 07, 2013 16:05 ET | Source: Receptos, Inc.

Receptos Reports Second Quarter 2013 Financial Results

- Phase 2 trials of RPC1063 continue to enroll patients globally - - Company capitalized to complete current Phase 2 trials - - Additional Phase 1 results of RPC1063 to be presented at ECTRIMS...
August 01, 2013 08:01 ET | Source: Receptos, Inc.

Receptos to Hold Second Quarter 2013 Financial Results Conference Call and Webcast

SAN DIEGO, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will...
July 22, 2013 08:00 ET | Source: Receptos, Inc.

Receptos Announces Appointment of Erle T. Mast as Director

SAN DIEGO, July 22, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
July 03, 2013 08:00 ET | Source: Receptos, Inc.

Receptos to Present at JMP Securities Healthcare Conference

SAN DIEGO, July 3, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
June 26, 2013 08:00 ET | Source: Receptos, Inc.

Receptos to be Added to Russell 3000(R) Index on June 28, 2013

SAN DIEGO, June 26, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...